RCM
AKBA icon

Rotella Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Rotella Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-12,500
Closed -$139K – 425
2015
Q1 		$139K Buy
+12,500
New +$133K 0.12% 304

Other funds holding AKBA

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Rotella Capital Management's AKBA Position: Q2 2015 in Review

Rotella Capital Management sold out of Akebia Therapeutics (AKBA) in Q2 2015, closing a stake of 12,500 shares — an estimated $139K sold.

Rotella Capital Management first reported a position in AKBA in Q1 2015 and held it in 1 quarter. The position peaked at $139K in Q1 2015. 73 funds tracked by Wall St. Rank hold AKBA as of Q2 2015.

  • Rotella Capital Management reported no remaining Akebia Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Rotella Capital Management sold 12,500 Akebia Therapeutics shares in Q2 2015, an estimated $139K.
  • Rotella Capital Management first reported a position in Akebia Therapeutics in Q1 2015 and held it in 1 quarter.
  • Rotella Capital Management's Akebia Therapeutics position peaked at $139K in Q1 2015.
  • 73 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2015.

Based on Rotella Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.